Literature DB >> 17526949

The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency.

Teresa C Vieira1, Magnus R Dias da Silva, Julio Abucham.   

Abstract

BACKGROUND: Combined pituitary hormone deficiency (CPHD) corresponds to impaired production of growth hormone (GH) and other anterior pituitary hormones. The genetic form of CPHD may result from mutations in pituitary transcription factor genes, and PROP1 is the most commonly mutated gene in these cases. Patients with PROP1 mutations may have variable CPHD phenotypes but, because they are usually treated in childhood, the wide phenotypic variability caused by these mutations may not be thoroughly appreciated.
METHODS: Clinical follow-up and molecular analysis of PROP1 in two adult brothers with CPHD, born from consanguineous parents, and not treated until late adulthood.
RESULTS: The homozygous R120C mutation was identified in the brothers. Their clinical follow-up showed a wide phenotypic variability: hypogonadism was severe and prevented pubertal development in both, but their final heights were remarkably different, pointing to different degrees in severity of GH/TSH deficiencies; cortisol deficiency developed late in both, but at least 10 yr apart.
CONCLUSIONS: The lack of treatment in childhood and adolescence allowed the appreciation of the entire natural history of the CPHD caused by the R120C mutation, and it revealed a remarkable phenotypic variability even in siblings with a very similar genetic background.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17526949     DOI: 10.1007/s12020-006-0015-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  33 in total

1.  MR imaging of the pituitary gland in children and young adults with congenital combined pituitary hormone deficiency associated with PROP1 mutations.

Authors:  O Fofanova; N Takamura; E Kinoshita; A Vorontsov; V Vladimirova; I Dedov; V Peterkova; S Yamashita
Journal:  AJR Am J Roentgenol       Date:  2000-02       Impact factor: 3.959

2.  Reversible kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene.

Authors:  Nelly Pitteloud; James S Acierno; Astrid U Meysing; Andrew A Dwyer; Frances J Hayes; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Mutations in PROP1 cause familial combined pituitary hormone deficiency.

Authors:  W Wu; J D Cogan; R W Pfäffle; J S Dasen; H Frisch; S M O'Connell; S E Flynn; M R Brown; P E Mullis; J S Parks; J A Phillips; M G Rosenfeld
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Variations in the pattern of pubertal changes in boys.

Authors:  W A Marshall; J M Tanner
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

5.  Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene.

Authors:  B B Mendonca; M G Osorio; A C Latronico; V Estefan; L S Lo; I J Arnhold
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

6.  Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion.

Authors:  G Agarwal; V Bhatia; S Cook; P Q Thomas
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

7.  PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis.

Authors:  Antje Böttner; Eberhard Keller; Jürgen Kratzsch; Heike Stobbe; Johannes F W Weigel; Alexandra Keller; Wolfgang Hirsch; Wieland Kiess; Werner F Blum; Roland W Pfäffle
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

8.  Familial combined pituitary hormone deficiency due to a novel mutation R99Q in the hot spot region of Prophet of Pit-1 presenting as constitutional growth delay.

Authors:  Teresa C Vieira; Magnus R Dias da Silva; Janete M Cerutti; Elisa Brunner; Mariana Borges; Liliane T Arnaldi; Peter Kopp; Julio Abucham
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg-->Cys at codon 120 (R120C).

Authors:  C Flück; J Deladoey; K Rutishauser; A Eblé; U Marti; W Wu; P E Mullis
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism.

Authors:  Kathryn S Woods; Maria Cundall; James Turton; Karine Rizotti; Ameeta Mehta; Rodger Palmer; Jacqueline Wong; W K Chong; Mahmoud Al-Zyoud; Maryam El-Ali; Timo Otonkoski; Juan-Pedro Martinez-Barbera; Paul Q Thomas; Iain C Robinson; Robin Lovell-Badge; Karen J Woodward; Mehul T Dattani
Journal:  Am J Hum Genet       Date:  2005-03-30       Impact factor: 11.025

View more
  4 in total

1.  Case seminar: a young female with acute hyponatremia and a sellar mass.

Authors:  Sandra Pekic; Mirjana Doknic; Dragana Miljic; Alexandru Saveanu; Rachel Reynaud; Anne Barlier; Thierry Brue; Vera Popovic
Journal:  Endocrine       Date:  2011-08-24       Impact factor: 3.633

2.  Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency.

Authors:  Helena Filipsson Nyström; Alexandru Saveanu; Edna J L Barbosa; Anne Barlier; Alain Enjalbert; Camilla Glad; Jenny Palming; Gudmundur Johannsson; Thierry Brue
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

Review 3.  The molecular basis of hypopituitarism.

Authors:  Christopher J Romero; Suzana Nesi-França; Sally Radovick
Journal:  Trends Endocrinol Metab       Date:  2009-10-23       Impact factor: 12.015

Review 4.  Combined pituitary hormone deficiency: current and future status.

Authors:  F Castinetti; R Reynaud; M-H Quentien; N Jullien; E Marquant; C Rochette; J-P Herman; A Saveanu; A Barlier; A Enjalbert; T Brue
Journal:  J Endocrinol Invest       Date:  2014-09-09       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.